Novo Nordisk's latest trial results for its next-generation obesity drug CagriSema disappointed investors ... to the company's existing Wegovy injection and rival Eli Lily's Zepbound, both GLP ...

A spokesperson confirmed the Danish drugmaker has asked U.S. regulators to clear an oral version of its weight loss drug ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

Today's Research Daily features new research reports on 16 major stocks, including The Procter & Gamble Company (PG), Novo ...

Novo Nordisk's hopes of heralding a new era of obesity treatment with its CagriSema drug have been ... to the company's existing Wegovy injection and rival Eli Lily's Zepbound, both GLP-1 ...